As we enter January 2026, the global markets are experiencing a dynamic shift, with small-cap stocks leading the charge over their large-cap counterparts. The S&P MidCap 400 and Russell 2000 indexes have reached all-time highs, reflecting strong investor interest in value stocks as earnings season unfolds. In this environment, identifying promising small-cap companies involves looking for those that demonstrate resilience amidst mixed market reactions and possess solid fundamentals that align with current economic indicators.

Top 10 Undervalued Small Caps With Insider Buying Globally

Name PE PS Discount to Fair Value Value Rating Tokmanni Group Oyj 12.6x 0.3x 44.51% ★★★★★☆ Paragon Care 17.7x 0.1x 20.61% ★★★★★☆ East West Banking 3.3x 0.8x 16.13% ★★★★☆☆ Vita Life Sciences 14.7x 1.6x 38.32% ★★★★☆☆ BWP Trust 10.5x 13.8x 9.62% ★★★★☆☆ Hung Hing Printing Group NA 0.4x 44.20% ★★★★☆☆ Nufarm NA 0.3x -137.71% ★★★★☆☆ Dicker Data 22.1x 0.8x -45.37% ★★★☆☆☆ Ever Sunshine Services Group 6.7x 0.4x -443.52% ★★★☆☆☆ PSC 9.9x 0.4x 18.55% ★★★☆☆☆

Click here to see the full list of 134 stocks from our Undervalued Global Small Caps With Insider Buying screener.

Let's uncover some gems from our specialized screener.

CVS Group

Simply Wall St Value Rating: ★★★☆☆☆

Overview: CVS Group operates veterinary practices, laboratories, and an online retail business with a market cap of approximately £1.33 billion.

Operations: CVS Group generates revenue primarily from its Veterinary Practices (£616.10 million) and Online Retail Business (£45.90 million), with a smaller contribution from Laboratories (£31.40 million). The company has experienced fluctuations in its gross profit margin, reaching 44.23% as of December 2023, after peaking at 44.03% earlier in September 2023. Operating expenses are significant, largely driven by General & Administrative costs, which were £209.9 million as of June 2025.

PE: 49.2x

CVS Group, operating in a niche industry, is considered undervalued due to its growth prospects and strategic financial maneuvers. Earnings are projected to increase by 18% annually, suggesting potential for future value appreciation. Despite relying solely on external borrowing for funding, insider confidence is evident with recent share purchases. A £20 million buyback program aims to optimize capital allocation and enhance shareholder value through Q1 2026. Interest coverage remains a concern but manageable within the current framework.

Take a closer look at CVS Group's potential here in our valuation report. Evaluate CVS Group's historical performance by accessing our past performance report.



AIM:CVSG Share price vs Value as at Jan 2026

Shanghai Haohai Biological Technology

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Shanghai Haohai Biological Technology is engaged in the production and sale of biologics, focusing on medical hyaluronic acid, with a market capitalization of CN¥12.34 billion.

Operations: The company's revenue primarily stems from the production and sale of biologics, particularly medical hyaluronic acid. The gross profit margin has shown a decreasing trend, moving from 86.66% in March 2015 to 68.38% by September 2025. Operating expenses are significant, with sales and marketing being the largest component, followed by research and development costs.

PE: 13.4x

Shanghai Haohai Biological Technology, a smaller company in the biotech industry, has recently seen insider confidence with Minjie Tang purchasing 10,000 shares for approximately CNY 248,600. This activity suggests potential optimism about future growth prospects. Despite relying entirely on external borrowing for funding—considered riskier than customer deposits—the company's earnings are projected to grow by 21.81% annually. Recent management changes include appointing Ms. Lai Ying Tung as Joint Company Secretary, enhancing corporate governance expertise within the firm.

Click here and access our complete valuation analysis report to understand the dynamics of Shanghai Haohai Biological Technology. Review our historical performance report to gain insights into Shanghai Haohai Biological Technology's's past performance.SEHK:6826 Ownership Breakdown as at Jan 2026

Killam Apartment REIT

Simply Wall St Value Rating: ★★★★☆☆

Overview: Killam Apartment REIT focuses on owning, operating, and developing a portfolio of residential apartment buildings, commercial properties, and manufactured home communities with a market capitalization of CA$2.12 billion.

Operations: Killam Apartment REIT generates revenue primarily from its apartment segment, contributing CA$334.42 million, followed by commercial and manufactured home communities (MHCs) segments. The company has seen a notable trend in its net income margin, which increased to 1.41% as of September 2025. Operating expenses include general and administrative costs, which amounted to CA$20.37 million for the same period.

PE: 3.9x

Killam Apartment REIT, a smaller real estate investment trust, shows potential as an undervalued asset despite some challenges. The company recently affirmed its monthly dividend of C$0.06 per unit for 2026, reflecting a consistent payout strategy. While sales increased to C$98 million in Q3 2025 from C$93 million the previous year, net income declined to C$42 million from C$63 million due to large one-off items affecting financial results. Despite external borrowing being its sole funding source, insider confidence is evident with recent share purchases by management in late 2025 and early 2026 indicating belief in future prospects.

Delve into the full analysis valuation report here for a deeper understanding of Killam Apartment REIT. Examine Killam Apartment REIT's past performance report to understand how it has performed in the past.TSX:KMP.UN Share price vs Value as at Jan 2026

Next Steps

Investigate our full lineup of 134 Undervalued Global Small Caps With Insider Buying right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready To Venture Into Other Investment Styles?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AIM:CVSG SEHK:6826 and TSX:KMP.UN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]